Ventures Fund Iv General Pa... Net Worth

The estimated Net Worth of Ventures Fund Iv General Pa... is at least $74 dollars as of 8 February 2021. Ventures Pa owns over 215,000 units of Kaleido Biosciences Inc stock worth over $74 and over the last 4 years Ventures sold KLDO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Pa KLDO stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Kaleido Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Ventures bought 215,000 units of KLDO stock worth $2,472,500 on 8 February 2021.

The largest trade Ventures's ever made was buying 215,000 units of Kaleido Biosciences Inc stock on 8 February 2021 worth over $2,472,500. On average, Ventures trades about 215,000 units every 0 days since 2021. As of 8 February 2021 Ventures still owns at least 738,333 units of Kaleido Biosciences Inc stock.

You can see the complete history of Ventures Pa stock trades at the bottom of the page.

Insiders trading at Kaleido Biosciences Inc

Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm, and Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.

What does Kaleido Biosciences Inc do?

the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.

Complete history of Ventures Pa stock trades at Kaleido Biosciences Inc

Kaleido Biosciences Inc executives and stock owners

Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:

• Jerald Korn,
  General Counsel, Corporate Secretary
• Katharine Knobil,
  Chief Medical Officer and Head of Research and Development
• William E. Duke Jr.,
  Chief Financial Officer
• Daniel L. Menichella B.A., M.B.A.,
  Pres, CEO & Director
• Jean Mixer,
  Independent Director
• Theo Melas-Kyriazi,
  Independent Director
• Michael Bonney,
  Chairman of the Board
• Anthony Quinn,
  Independent Director
• Grady Burnett,
  Independent Director
• Bonnie Bassler,
  Independent Director
• Anne Prener,
  Independent Director
• William Duke,
  Chief Financial Officer
• Daniel Menichella,
  President, Chief Executive Officer, Principal Executive Officer
• Dr. Alison Long M.D., Ph.D.,
  Chief Medical Officer
• Dr. Mark A. Wingertzahn Ph.D.,
  Sr. VP of R&D and Head of Devel.
• Susan Stewart J.D.,
  Chief Regulatory Affairs – Advisor
• Dr. Johan Van Hylckama Vlieg Ph.D.,
  Chief Scientific Officer
• Kimberly Hocknell,
  Sr. VP of Technical Operations
• Jerald Korn J.D.,
  COO, Gen. Counsel & Corp. Sec.
• Dr. Geoffrey von Maltzahn Ph.D.,
  Co-Founder & Director
• Hylckama Vlieg Johan Van,
  Chief Scientific Officer
• Ventures Fund Iv General Pa...,
  
• Joshua T Brumm,
  See Remarks
• Alison Frances Lawton,
  See Remarks
• Maltzahn Geoffrey Von,
  Director
• Ventures Fund V General Par...,
  
• Ventures Fund Iv General Pa...,
  
• Ventures Fund Iv General Pa...,
  
• Alison S Long,
  Chief Medical Officer